-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

617A.O2.6 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Genomic Lesions and Therapeutic Implications Clinically Relevant Abstract

Symposia: Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, clinical trials, Acute Myeloid Malignancies, AML, MDS, adult, Translational Research, epidemiology, Clinical Research, Combination therapy, drug development, Chronic Myeloid Malignancies, Diseases, Therapies, therapy sequence, Myeloid Malignancies, survivorship, Technology and Procedures, Study Population, Human, Minimal Residual Disease , molecular testing
Saturday, December 10, 2022: 2:00 PM-3:30 PM
291-292 (Ernest N. Morial Convention Center)
Moderators:
Jatinder K. Lamba, PhD, University of Florida, College of Pharmacy, Pharmacotherapy and Translational Re and Rong He, MD, Mayo Clinic
Disclosures:
He: Kura Oncology, Inc: Consultancy.
2:00 PM

Hartmut Döhner, MD1, Dylan M. Marchione, PhD2*, Sung Choe2*, Pau Montesinos, MD, PhD3*, Christian Recher, MD4, Susana Vives, PhD5*, Ewa Zarzycka, MD6*, Jianxiang Wang7*, Claudio Cerchione, MD8, Michael Heuser, MD9, Rodrigo T. Calado, MD, PhD10,11, Andre C. Schuh, MD12, Su-Peng Yeh, MD13*, Adolfo De La Fuente, MD14*, Jianan Hui, PhD2*, Prapti Patel, MD15*, Diego A. Gianolio, PhD2*, Scott R. Daigle, MS2*, Courtney D. DiNardo, MD, MSCE16 and Stephane De Botton, MD17*

1Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany
2Servier Pharmaceuticals, Boston, MA
3Hospital Universitari i Politècnic La Fe, Instituto de Investigación Sanitaria La Fe (IISLAFE), Valencia, Spain
4Service d'Hématologie, CHU de Toulouse - Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France
5ICO-Hospital Germans Trias i Pujol, Badalona, Spain
6Department of Hematology and Transplantology, Medical University, Gdansk, Poland
7Institute of Hematology & Hospital of Blood Disease – Peking Union Medical College, Tianjin, China
8Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola (FC), Italy
9Department for Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
10Department of Medical Imaging, Hematology and Clinical Oncology, Ribeirão Preto School of Medicine, University of São Paulo, São Paulo, Brazil
11Department of Medical Imaging, Hematology, and Clinical Oncology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil
12Princess Margaret Cancer Centre, Toronto, ON, Canada
13China Medical University Hospital, Taichung, Taiwan
14MD Anderson Cancer Center, Madrid, ESP
15Servier Pharmaceuticals, Boston
16Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
17Institut Gustave Roussy, Villejuif, France

2:15 PM

Walid Macaron, MD, MSc1*, Farhad Ravandi, MD1, Tapan M. Kadia, MD2, Courtney D. DiNardo, MD, MSCE1, Ghayas C. Issa, MD1, Naval Daver, MD1, Sa A Wang, MD3*, Jeffrey L. Jorgensen, MD, PhD3*, Keyur Patel, MD, PhD3*, Sanam Loghavi, MD3, Marina Konopleva, MD, PhD4, Musa Yilmaz, MD2, Elias Jabbour, MD1, Abhishek Maiti, MBBS5, Hussein A Abbas, MD, PhD1, Elizabeth J Shpall, MD6, Uday R Popat, MD6, Gheath Alatrash, PhD, DO6, Sherry A. Pierce, BSN, BA1*, Hagop Kantarjian, MD7 and Nicholas Short, MD4

1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2Department of Leukemia, MD Anderson Cancer Center, Houston, TX
3Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
4Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
5Department of Leukemia, The University of Texas Health Science Center At Houston, Houston, TX
6Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
7Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

2:30 PM

Mark J. Levis, MD1,2, Harry P. Erba, MD, PhD3, Pau Montesinos, PhD, MD4*, Radovan Vrhovac, MD, PhD5*, Elzbieta Patkowska6*, Heeje Kim, M.D., Ph.D.7, Pavel Zak, MD, PhD8*, Po-Nan Wang, MD9, Jaime E. Connolly Rohrbach10*, Ken CN Chang, PhD11*, James Hanyok, PharmD10*, Li Liu10*, Yasser Mostafa Kamel, MD11*, Arnaud Lesegretain12*, Jorge E. Cortes, MD13, Mikkael A. Sekeres, MD14, Hervé Dombret, MD PhD15, Sergio Amadori, MD16, Jianxiang Wang, MD17, Richard F. Schlenk, MD18 and Alexander Perl, MD19

1Division of Hematologic Malignancies, Johns Hopkins University, Baltimore, MD
2Director, Adult Leukemia Program, Co-Division Director, Hematologic Malignancies, Professor of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, Baltimore, MD
3Leukemia Program, Duke University Medical Center, Durham, NC
4Hospital Politecnico Universitario La Fe, Valencia, Spain, Spain
5University Hospital Centre Zagreb, Zagreb, HRV
6Hematology Department, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
7Catholic Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South)
8Internal Medicine IV – Hematology, University Hospital and Charles University, Faculty of Medicine in Hradec Kralove, Hradec Kralove, Czech Republic
9Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan
10Daiichi Sankyo, Inc, Basking Ridge, NJ
11Daiichi Sankyo, Inc., Basking Ridge, NJ
12Daiichi Sankyo Inc., Basking Ridge, NJ
13Georgia Cancer Center Augusta University, Augusta, GA
14University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL
15Hopital Saint-Louis, Assistance Publique - Hopitaux De Paris (AP-HP), Paris, FRA
16Tor Vergata Polyclinic Hospital Rome, Rome, RM, Italy
17Institute of Hematology, CAMS, Tianjin, China
18National Center of Tumor Diseases, Heidelberg, Heidelberg, Germany
19Division of Hematology-Oncology/Department of Medicine, University of Pennsylvania, Philadelphia, PA

2:45 PM

Pierre Hirsch1,2*, Jérôme Lambert, MD, PhD3*, Maxime Bucci4*, Caroline Deswarte, MSc5*, Juliette Lambert, MD, PhD6*, Laurène Fenwarth, MD, MSc4,7*, Herve Dombret, MD PhD8, Nicolas Duployez, PharmD, PhD4*, Claude Preudhomme, PharmD, PhD4, Raphael Itzykson, MD, PhD9 and Francois Delhommeau, PharmD-PhD2,5*

1Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, Paris, France, Paris, France
2APHP, Hôpital Saint Antoine, Laboratoire d'hématologie Biologique, Paris, France, Paris, France
3Biostatistics Department, Hôpital Saint Louis, APHP, Paris, France
4Laboratory of Hematology, CHU Lille, Lille, France
5Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, AP-HP, Hôpital Saint-Antoine, Paris, France
6Hôpital de Versailles, Le Chesnay, France
7University of Lille, Lille, France
8Hopital Saint-Louis, Assistance Publique - Hopitaux De Paris (AP-HP), Paris, FRA
9Department of Hematology, Hôpital Saint-Louis, Paris, France

3:00 PM

Alberto Hernández Sánchez, MD1,2*, Teresa González, PhD2,3*, Marta Anna Sobas, MD, PhD4*, Eric Sträng, PhD5*, Castellani Gastone, PhD6*, María Abáigar3,7*, Peter JM Valk, PhD8, Angela Villaverde Ramiro2,3*, Axel Benner9*, Klaus H Metzeler, MD10, Jesse M. Tettero11*, Joaquín Martínez-López, MD, PhD12*, Marta Pratcorona, MD13*, Javier Martinez Elicegui2,3*, Ken I Mills, BSc, PhD, FRCPath14, Christian Thiede, MD15, Guillermo Sanz, MD, PhD16,17, Konstanze Döhner, MD18, Michael Heuser, MD19, Torsten Haferlach, MD20, Amin T. Turki, MD21, Dirk Reinhardt, MD22, Renate Schulze-Rath23*, Martje Barbus, PhD24*, Jesús María Hernández-Rivas, MD, PhD1,2,3, Brian Huntly, MB ChB, FRCPath, FMedSci, PhD25, Gert Ossenkoppele, MD26, Hartmut Döhner, MD27 and Lars Bullinger, MD28

1Hematology Department, University Hospital of Salamanca, Salamanca, Spain
2Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain
3Cancer Research Center of Salamanca (USAL-CSIC), Salamanca, Spain
4Wroclaw Medical University, Wroclaw, Poland
5Charité Universitätsmedizin Berlin, Berlin, Germany
6DIMES, University of Bologna, Bologna, Italy
7Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain
8Department of Hematology, Erasmus University Medical Center Cancer Institute, Rotterdam, Netherlands
9Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany
10University of Leipzig, Germany, Leipzig, Germany
11Department of Hematology, Amsterdam University Medical Center location Vrije Universiteit Amsterdam, Amsterdam, Netherlands
12Hospital Universitario 12 de Octubre, Madrid, Spain
13Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
14Queen's University Belfast, Belfast, United Kingdom
15University of Technics Dresden Medical Dept., Dresden, Germany
16CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
17Hospital Universitario y Politécnico La Fe, Valencia, Spain
18Division of Hematology and Oncology, University Hospital Ulm, Ulm, Germany
19Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
20MLL Munich Leukemia Laboratory, Munich, Germany
21Department of Hematology and Stem Cell Transplantation, University Hospital of Essen, Essen, Germany
22Department of Pediatrics III, University Hospital Essen, University Duisburg-Essen, Essen, Germany
23Bayer AG, Pharmaceuticals Division, Berlin, Berlin, Germany
24AbbVie Deutschland GmbH & Co KG, Wiesbaden, DEU
25Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, ENG, United Kingdom
26Amsterdam University Medical Center, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, Netherlands
27Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
28Department of Hematology, Oncology, and Tumor Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany

3:15 PM

Sandra Huber, PhD*, Constance Baer, PhD, Stephan Hutter, PhD*, Frank Dicker, PhD, Manja Meggendorfer, PhD, Christian Pohlkamp, MD*, Wolfgang Kern, MD, Torsten Haferlach, MD, Claudia Haferlach, MD and Gregor Hoermann, MD, PhD

MLL Munich Leukemia Laboratory, Munich, Germany

*signifies non-member of ASH